Laura Griffith
Medtronic plc
Public Relations
     Ryan Weispfenning
Medtronic plc
Investor Relations
     Shane Hoffman

Medtronic and ChristianaCare Collaborate to Improve Patient Outcomes and Reduce Cost of Care in Delaware

Value-Based Healthcare Collaboration Designed to Help ChristianaCare Apply Right Therapies to Patients Who May Benefit Most

Medtronic plc (NYSE:MDT) and ChristianaCare today announced a collaboration designed to improve outcomes for ChristianaCare patients in Delaware and the surrounding region. The five-year agreement will focus on developing and deploying value-based healthcare initiatives to help ChristianaCare apply the right medical technologies and therapies to patients who may benefit most, with shared financial accountability between ChristianaCare and Medtronic to improve patient outcomes while reducing the cost of care.

“There’s general consensus that a fee-for-service system is not sustainable, and a value-based system is the way to go, but ‘how’ becomes a question. We want to take that on, but transformation can only happen through collaboration with others with aligned views and aligned reward mechanisms,” said Omar Ishrak, chairman and chief executive officer of Medtronic. “ChristianaCare’s shared commitment to developing value-based healthcare initiatives makes them an ideal partner for Medtronic.”

“We are committed to delivering health — not just healthcare — to the people we serve,” said Janice E. Nevin, M.D., MPH, president and chief executive officer of ChristianaCare. “Value-based care is the key to achieving optimal health and an exceptional experience for the people we serve, while ensuring that care is accessible and affordable.”

One of the first initiatives is expected to address opioid-induced ventilatory impairment (OIVI), which occurs when opioids used for pain management inhibit the central drive to breathe and may cause the patient to stop breathing completely unless clinicians intervene with life-saving measures. Medtronic and ChristianaCare seek to standardize an enhanced respiratory monitoring initiative to help address OIVI. This initiative will be designed to identify patients receiving opioids for pain management who are at high risk for OIVI and apply continuous monitoring technology to track breathing, and help alert the care team to abnormal trends.

Other initiatives are expected to address heart failure and diabetes, which together affect more than 35 million people in the United States and cost the nation an estimated $357 billion each year, according to the Centers for Disease Control and Prevention.1,2, This work is designed to enhance ChristianaCare’s ability to prevent or slow disease progression, reduce hospitalizations, and lower overall cost of care for patients with these chronic conditions.

“Together with Medtronic, we are aligning expertise and incentives to exponentially increase our ability to achieve optimal health — not just better care delivery,” said Randall Gaboriault, M.S., chief digital and information officer and senior vice president, innovation and strategic development at ChristianaCare. “This collaboration will implement a new value chain, based on vested purpose, co-innovation, digital and data.”

Learnings from this collaboration have the potential to impact health far beyond the Delaware region. Delaware’s demographics and ChristianaCare’s diverse patient population across a broad spectrum of healthcare settings create an ideal test ground for the organizations to develop and scale new value-based initiatives that could benefit the health of patient populations across the country.

“We recognize that creating healthier communities requires integrated care models, passion to improve the status quo, and an aligned purpose of helping patients live healthier and fuller lives,” said John Liddicoat, M.D., executive vice president and president of the Americas Region at Medtronic. “This collaboration with ChristianaCare reinforces our joint commitment to healthcare innovation through value-based arrangements.”

About ChristianaCare
Headquartered in Wilmington, Delaware, ChristianaCare is one of the country’s most dynamic health care organizations, centered on improving health outcomes, making high-quality care more accessible and lowering health care costs. ChristianaCare includes an extensive network of outpatient services, home health care, medical aid units, two hospitals (1,227 beds), a Level I trauma center and a Level III neonatal intensive care unit, a comprehensive stroke center and regional centers of excellence in heart and vascular care, cancer care and women’s health. It also includes the pioneering Gene Editing Institute and was rated by IDG Computerworld as one of the nation’s Best Places to Work in IT. ChristianaCare is a not-for-profit teaching health system with more than 260 residents and fellows. We are continually ranked by US News & World Report as a Best Hospital. With our unique, data-powered CareVio care coordination service and a focus on population health and value-based care, ChristianaCare is shaping the future of health care. Learn how we deliver greater quality and value at

About Medtronic
Medtronic plc (, headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take health care Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1 CDC Heart Failure Fact Sheet:
2 CDC Diabetes Quick Facts: